Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer ; volume:15 ; number:2 ; day:12 ; month:2 ; year:2024 ; pages:1-13 ; date:2.2024
Cell death & disease ; 15, Heft 2 (12.2.2024), 1-13, 2.2024
- Creator
-
Dash, Suman
Ueda, Takeshi
Komuro, Akiyoshi
Honda, Masahiko
Sugisawa, Ryoichi
Okada, Hitoshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-024-06531-x
- URN
-
urn:nbn:de:101:1-2404220820193.583686299946
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dash, Suman
- Ueda, Takeshi
- Komuro, Akiyoshi
- Honda, Masahiko
- Sugisawa, Ryoichi
- Okada, Hitoshi
- SpringerLink (Online service)
Other Objects (12)
Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
Erratum to: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway
Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer
Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts
Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Quantum interference enhances the performance of single-molecule transistors
Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
Erratum to: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway
Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer
Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts
Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms
Quantum interference enhances the performance of single-molecule transistors
Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
Erratum to: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway
Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer
Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts
Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms